免疫性血小板减少症(ITP)患者调查:识别美国患者治疗与疾病控制相关未满足需求
该横断面真实世界证据调查由血小板疾病支持协会与赛诺菲于2023年2月9日至2023年4月4日开展,纳入确诊ITP≥1年的美国成人患者。结果显示多数患者接受并坚持治疗,但缺乏持续疗效推动对更有效疗法的需求,患者最关注提升/稳定血小板计数及减轻疲劳和出血严重程度。
要点
- 多数患者接受并坚持治疗,但缺乏持续疗效推动对更有效疗法的需求。
- 患者最关注提升/稳定血小板计数以及减轻疲劳和出血严重程度。
- 患者偏好参与共享决策以及教育、数字医疗和心理支持等患者支持选项。
核心结论
- ITP患者期望长期疾病管理方案能改善血小板计数、减少出血并减轻身体疲劳和焦虑,同时参与患者支持选项。
研究设计与样本
- 横断面真实世界证据调查,由血小板疾病支持协会与赛诺菲于2023年2月9日至2023年4月4日开展,纳入确诊ITP≥1年的美国成人患者。
主要发现
- 多数患者接受并坚持治疗,但缺乏持续疗效推动对更有效疗法的需求。
- 患者期望长期ITP控制,最关注提升/稳定血小板计数以及减轻疲劳和出血严重程度。
- 需要更好的治疗以缓解负担沉重的健康相关生活质量症状,尤其是身体疲劳和焦虑,并减少对日常生活和活动的影响。
- 患者偏好参与共享决策以及教育、数字医疗和心理支持。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is a chronic disease with primary therapeutic goals of platelet count recovery to safe levels to minimize active/future bleeding, alongside easing additional symptoms negatively impacting overall patient well-being with consequent improvement in physical fatigue/energy levels, daily/work-related activities and social/emotional health. Documentation of this rare disease is important for evaluating real-world experiences in treatment satisfaction, expectations and unmet needs in disease management. This cross-sectional, real-world evidence survey was conducted from 9 February 2023 to 4 April 2023, by the Platelet Disorder Support Association and Sanofi in US adults diagnosed with ITP for ≥1 year. Results showed that although most patients receive and adhere to treatment, lack of sustained efficacy fuels a need for more effective therapy. Patients desired long-term ITP control and were most concerned with increasing/stabilizing platelet counts and decreasing fatigue and bleeding severity. Better treatment was needed to ease burdensome health-related quality of life symptoms, especially physical fatigue and anxiety, and decrease effects on daily life and activities. Additionally, involvement in shared decision-making and engagement in educational, digital healthcare and psychological support were preferred. Overall, ITP patients desired long-term disease management options that improved platelet counts, minimized bleeding and reduced physical fatigue and anxiety, while also engaging in patient support options.
引用
- Cooper N, Kruse C, Deneen Morgan S, et al. Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States. Br J Haematol. 2025. PMID: 40820557. doi:10.1111/bjh.20257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。